No established standard of care exists for aggressive cutaneous squamous cell carcinoma (CSCC).
We sought to establish an aggressive CSCC management protocol by reviewing high-risk CSCC (HCSCC) and very high-risk CSCC (VCSCC) cases at our institution.
This was a retrospective review of all CSCC cases treated at our institution.
A total of 27 patients were identified of 1591 cases treated between 2000 and 2011. Four patients with HCSCC received surgery alone and 1 received surgery and radiation. All remain disease free (median follow-up 5 years). Among patients with VCSCC, 4 received surgery alone: 1 (25%) showing a complete response and 3 (75%) showing disease progression. Eleven received surgery and radiation: 4 (36.4%) with complete response (median follow-up 3 years) and 7 (63.6%) with disease progression (median time to recurrence 6 months). Six received surgery and cetuximab: 3 (50%) had a complete response (median follow-up 3 years), 2 (33%) had disease progression, and 1 (14%) could not be assessed because of inability to tolerate infusions. One patient received surgery, cetuximab, and radiation, and remains disease-free after 4 years.
Lack of randomization, blinding, a true control arm, or standardization of treatment protocols are limitations.
Patients with very HCSCC may have improved outcomes with surgery and adjuvant cetuximab.Le texte complet de cet article est disponible en PDF.
Key words : carcinoma, cetuximab, cutaneous, epidermal growth factor receptor, radiation, skin, squamous
Abbreviations used : CR, CSCC, EGFR, HCSCC, SCC, SCCHN, VCSCC
| Funding sources: None.
| Conflicts of interest: None declared.
| Presented at the 2012 American College of Mohs Surgery Annual Meeting, Chicago, IL, May 2012.